Relevant publications TROP

The long- and short-term variability of breathing induced tumor motion in lung and liver over the course of a radiotherapy treatment.
Dhont J, Vandemeulebroucke J, Burghelea M, Poels K, Depuydt T, Van Den Begin R, Jaudet C, Collen C, Engels B, Reynders T, Boussaer M, Gevaert T, De Ridder M, Verellen D. Radiother Oncol. 2018 Feb;126(2):339-346.

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de Ridder M. Clin Transl Oncol. 2017 Aug 9.

Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H, Bouzakoura S, de Mey S, Jiang H, Law K, Dufait I, Corbet C, Verovski V, Gevaert T, Feron O, Van den Berge D, Storme G, De Ridder M. Oncotarget. 2017 May 30;8(22):35728-35742.

Treating patients with Dynamic Wave Arc: First clinical experience.
Burghelea M, Verellen D, Dhont J, Hung C, Gevaert T, Van den Begin R, Collen C, Poels K, Tournel K, Boussaer M, Jaudet C, Reynders T, Simon V, de Ridder M. Radiother Oncol. 2017 Mar;122(3):347-351.

Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.
Leonard W, Dufait I, Schwarze JK, Law K, Engels B, Jiang H, Van den Berge D, Gevaert T, Storme G, Verovski V, Breckpot K, De Ridder M. Radiother Oncol. 2016 May;119(2):291-9.

More publications:

https://www.ncbi.nlm.nih.gov/pubmed/?term=De+Ridder+M+AND+Brussel